Grupos de investigación

  1. Portada
  2. Publicaciones
  3. Publicaciones 2004-2006

Publicaciones 2004-2006

Publicaciones anteriores

  1. “VIP and tolerance induction in autoimmunity”. Rosignoli F, Torroba M, Juarranz Y, García-Gómez M, Martínez C, Gomariz RP, Pérez-Leirós C, Leceta J. Ann N Y Acad Sci. 2006 Jul;1070:525-30.
  2. “PAC1 receptor: emerging target for septic shock therapy”. Martínez C, Arranz A, Juarranz Y, Abad C, García-Gómez M, Rosignoli F, Leceta J, Gomariz RP. Ann N Y Acad Sci. 2006 Jul;1070:405-10.
  3. “VIP decreases TLR4 expression induced by LPS and TNF-alpha treatment in human synovial fibroblasts”. Juarranz Y, Gutiérrez-Cañas I, Arranz A, Martínez C, Abad C, Leceta J, Pablos JL, Gomariz RP. Ann N Y Acad Sci. 2006 Jul;1070:359-64.
  4. “Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis”. Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J, Gomariz RP, Martínez C. Ann N Y Acad Sci. 2006 Jul;1070:129-34.
  5. “VIP-PACAP system in immunity: new insights for multitarget therapy”. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martínez C. Ann N Y Acad Sci. 2006 Jul;1070:51-74.
  6. “Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP”. Abad C, Gomariz RP, Waschek JA. Curr Top Med Chem. 2006;6(2):151-63.
  7. “VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts”. Gutiérrez-Cañas I, Juarranz Y, Santiago B, Arranz A, Martínez C, Galindo M, Payá M, Gomariz RP, Pablos JL. Rheumatology (Oxford). 2006 May;45(5):527-32. PDF
  8. “CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans”. Santiago B, Baleux F, Palao G, Gutiérrez-Cañas I, Ramírez JC, Arenzana-Seisdedos F, Pablos JL. Arthritis Res Ther. 2006;8(2):R43. PDF
  9. “Defective signalling in salivary glands precedes the autoimmune response in the non-obese diabetic mouse model of sialadenitis”. Rosignoli F, Roca V, Meiss R, Leceta J, Gomariz RP, Pérez Leirós C. Clin Exp Immunol. 2005 Dec;142(3):411-8. PDF
  10. “Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis”. Juarranz Y, Abad C, Martínez C, Arranz A, Gutiérrez-Cañas I, Rosignoli F, Gomariz RP, Leceta J. Arthritis Res Ther. 2005;7(5):R1034-45. PDF
  11. “cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP”. Abad C, Juarranz Y, Martínez C, Arranz A, Rosignoli F, García-Gómez M, Leceta J, Gomariz RP. Inflamm Bowel Dis. 2005 Jul;11(7):674-84.
  12. “Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP”. Gomariz RP, Arranz A, Abad C, Torroba M, Martínez C, Rosignoli F, Garcia-Gómez M, Leceta J, Juarranz Y. J Leukoc Biol. 2005 Aug;78(2):491-502. PDF
  13. “Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock”. Martínez C, Juarranz Y, Abad C, Arranz A, Miguel BG, Rosignoli F, Leceta J, Gomariz RP. J Leukoc Biol. 2005 May;77(5):729-38. PDF
  14. “Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis”. Santiago B, Gutiérrez-Cañas I, Dotor J, Palao G, Lasarte JJ, Ruiz J, Prieto J, Borrás-Cuesta F, Pablos JL. J Invest Dermatol. 2005 Sep;125(3):450-5. PDF
  15. “Coexpression of AT1 and AT2 receptors by human fibroblasts is associated with resistance to angiotensin II”. Galindo M, Santiago B, Palao G, Gutiérrez-Cañas I, Ramirez JC, Pablos JL. Peptides. 2005 Sep;26(9):1647-53.
  16. “Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K”. Gutiérrez-Cañas I, Juarranz MG, Collado B, Rodríguez-Henche N, Chiloeches A, Prieto JC, Carmena MJ. Prostate. 2005 Apr 1;63(1):44-55.
  17. “Induction of neuropeptide gene expression and blockade of retrograde transport in facial motor neurons following local peripheral nerve inflammation in severe combined immunodeficiency and BALB/C mice”. Armstrong BD, Hu Z, Abad C, Yamamoto M, Rodríguez WI, Cheng J, Lee M, Chhith S, Gomariz RP, Waschek JA. Neuroscience. 2004;129(1):93-9.
  18. “Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells”. Juarranz MG, Santiago B, Torroba M, Gutiérrez-Cañas I, Palao G, Galindo M, Abad C, Martínez C, Leceta J, Pablos JL, Gomariz RP. Rheumatology (Oxford). 2004 Apr;43(4):416-22. PDF
  19. “Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells”. Collado B, Gutiérrez-Cañas I, Rodríguez-Henche N, Prieto JC, Carmena MJ. Regul Pept. 2004 Jun 15;119(1-2):69-75.